{"filing":{"accession_number":"0001193125-26-255396","cik":"0001582313","ticker":"XENE","company_name":"Xenon Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"xene-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526255396/xene-20260602.htm"},"events":[{"id":7153,"run_id":6277,"accession_number":"0001193125-26-255396","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Xenon Pharmaceuticals held its Annual Meeting of shareholders on June 2, 2026, with voting results on six proposals including election of eight directors, advisory say-on-pay approval, say-on-pay frequency (1-year), approval of the 2026 Equity Incentive Plan, appointment of PricewaterhouseCoopers LLP as auditor, and auditor remuneration authority. All proposals passed with strong shareholder majorities.","company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3955,"accession_number":"0001193125-26-255396","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan, which replaces the prior 2014 plan. This is a compensatory arrangement for officers and directors involving equity grants and incentive structures. The plan was approved at the June 2, 2026 annual meeting upon Board recommendation, making it a material governance and compensation event affecting executive compensation frameworks.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:23:03.509510+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3956,"accession_number":"0001193125-26-255396","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of Xenon Pharmaceuticals' Annual Meeting of shareholders, including voting outcomes on six proposals: election of eight directors (all passed with strong majorities), advisory say-on-pay approval, say-on-pay frequency (1-year), 2026 Equity Incentive Plan approval, appointment of PricewaterhouseCoopers LLP as auditor, and auditor remuneration authority. The disclosure is material as it confirms shareholder approval of key governance and compensation matters affecting the company's leadership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:23:03.509510+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3955,"accession_number":"0001193125-26-255396","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan, which replaces the prior 2014 plan. This is a compensatory arrangement for officers and directors involving equity grants and incentive structures. The plan was approved at the June 2, 2026 annual meeting upon Board recommendation, making it a material governance and compensation event affecting executive compensation frameworks.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:23:03.509510+00:00","company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","filing_date":"2026-06-03"},{"id":3956,"accession_number":"0001193125-26-255396","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of Xenon Pharmaceuticals' Annual Meeting of shareholders, including voting outcomes on six proposals: election of eight directors (all passed with strong majorities), advisory say-on-pay approval, say-on-pay frequency (1-year), 2026 Equity Incentive Plan approval, appointment of PricewaterhouseCoopers LLP as auditor, and auditor remuneration authority. The disclosure is material as it confirms shareholder approval of key governance and compensation matters affecting the company's leadership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:23:03.509510+00:00","company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","filing_date":"2026-06-03"}]}